Adze Biotechnology's self-amplifying oncolytic viruses target and kill local and disseminated cancer cells, leaving healthy cells unaffected.
Our vectors also act as platforms to safely deliver potent immunostimulatory and immune evasion blocking proteins into tumors.
Our oncolytic vectors kill cancer cells directly, exposing cancer antigens to the immune system, while the immunotherapy payloads stimulate the patient's own immune response.
After the first cancer cells are executed, local and distant cancer cells are infected and the oncolytic and immunotherapeutic wave propagates.
Our vectors also target the same immune evasion checkpoints as current therapies by delivering immune evasion blocking proteins to cancer cells.
Adze's oncolytic vectors have modified surface proteins, which allows for more versatile and potent vectors. These modifications improve macrophage evasion for increased potency at reduced dosing levels.
Our virotherapy platform targets the same immune checkpoints as current therapies, but also kills cancer cells and exposes cancer antigens to the immune system.
Proprietary modifications to our viral particles help escape circulating macrophages
for improved potency.
ADZ Hexon proteins are designed to evade scavenger receptors in the liver's Kupffer cells. These modifications allow for greater systemic anti-cancer therapy activity.
Copyright © 2018 Adze Biotechnology - All Rights Reserved.